Abenacianine for Lung Cancer Surgery

This study is looking at a drug called Abenacianine (VGT-309) to help doctors find cancer during lung surgery. Abenacianine is given through an IV and works with a special camera (Near Infrared or NIR imaging) to highlight cancer cells. The goal is to see how well Abenacianine helps identify cancer and if it's safe. You might be able to join if you are at least 18 years old and are scheduled for lung surgery to remove a lesion or mass. The study aims to enroll about 132 participants. The study status is currently unclear.

Study design
This is a Phase 3, multi-center study that will compare participants receiving Abenacianine with NIR imaging to a control group receiving Abenacianine without NIR imaging. Approximately 132 participants will be enrolled.
What's involved
You will receive Abenacianine through an IV and undergo NIR imaging during your lung surgery. The primary endpoint is measured on the day of surgery.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured on the day of surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07499674

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Recruiting
PHASE3Ages 18+InterventionalTreatment
Vergent Bioscience, Inc.
~132 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:AbenacianineNear Infrared (NIR) Imaging

At a glance

Recruiting sites
8 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identify the proportion of participants with at least one Clinically Significant Event (CSE) as defined by:
Measured over Day of Surgery
Lung Cancer
Lung Metastases
9 sites across 8 states
California2
Colorado1
Florida1
Michigan1
Minnesota1
Pennsylvania1
Texas1
Victoria1
  • Curtis Scribner, MD · STUDY_DIRECTOR · Vergent Bio

Opens a ready-to-send draft in your own email app — review before sending.

  • Identify the proportion of participants with at least one Clinically Significant Event (CSE) as defined by:Day of Surgery

    A. Intraoperative localization of one or more preoperatively identified lung lesions using abenacianine with NIR imaging when standard surgical techniques using white light with or without palpation fail to identify the lesion(s). B. Identification of one or more synchronous or occult lung lesions using abenacianine with NIR imaging when standard surgical techniques using white light with or without palpation and preoperative imaging fail to identify the lesion(s).